



Corrigendum

Corrigendum to “Leuprorelin combined with letrozole with/without everolimus in ovarian-suppressed premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer: The LEO study” [Eur J Canc 144 (2021) 341–350]



Jae Ho Jeong ^a, Jeong Eun Kim ^a, Jin-Hee Ahn ^a, Kyung Hae Jung ^a, Su-Jin Koh ^b, Jaekyung Cheon ^b, Joohyuk Sohn ^c, Gun Min Kim ^c, Keun Seok Lee ^d, Sung Hoon Sim ^d, In Hae Park ^{d,e}, Sung-Bae Kim ^{a,*}

^a Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, South Korea

^b Division of Hematology and Oncology, Ulsan University Hospital, Ulsan, South Korea

^c Division of Medical Oncology, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea

^d Center for Breast Cancer, National Cancer Center, Goyang, South Korea

^e Division of Medical Oncology, Department of Internal Medicine, Korea University Guro Hospital, South Korea

The authors regret that the numbers of bone metastasis in this LEO trial (Table 1) need to be corrected as follows:

Bone meta 59 (64.1)→ 66 (71.7)in the EVE arm.

27 (60.0)→ 31 (71.1) in the LET arm.

Please find the correct Table 1 below. These corrections do not affect any description in the published article.

The authors would like to apologise for any inconvenience caused.

Table 1

Patient characteristics.

Characteristics	EVE arm (n = 92)	LET arm (n = 45)
Age, years, median (range)	44 (24–54)	45 (25–56)
ECOG performance status		
0	49 (53.3)	22 (48.9)
1	42 (45.7)	23 (51.1)
2	1 (1.1)	0
Visceral disease	56 (60.9)	27 (60.0)

(continued on next page)

DOI of original article: <https://doi.org/10.1016/j.ejca.2020.11.044>.

* Corresponding author: Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, 88, Olympic-ro 43-gil, Songpa-gu, Seoul 05505, South Korea.

E-mail address: sbkim3@amc.seoul.kr (S.-B. Kim).

<https://doi.org/10.1016/j.ejca.2021.02.004>

0959-8049/© 2021 Elsevier Ltd. All rights reserved.

Table 1 (continued)

Characteristics	EVE arm (n = 92)	LET arm (n = 45)
Bone only disease	5 (5.4)	6 (13.3)
Previous sensitivity to endocrine therapy* (%)	68 (73.9)	34 (75.6)
Previous endocrine therapy		
Tamoxifen	54 (58.7)	26 (57.8)
Tamoxifen → GnRH agonist	18 (19.6)	9 (20.2)
Tamoxifen + GnRH agonist	20 (21.7)	10 (22.2)
Previous chemotherapy	15 (16.3)	6 (13.3)
Measurable disease	83 (90.2)	39 (86.7)
Number of metastatic sites		
1	26 (28.3)	15 (33.3)
2	29 (31.5)	14 (31.1)
≥3	37 (40.2)	16 (35.6)
Site of metastasis		
Lung	29 (31.5)	18 (40.0)
Liver	25 (27.2)	12 (26.7)
Bone	66 (71.7)	32 (71.1)
Purpose of the most recent treatment		
Adjuvant therapy	45 (48.9)	26 (57.8)
Palliative therapy	47 (51.1)	19 (42.2)
Line of treatment		
1 st line	45 (48.9)	26 (57.8)
2 nd line	31 (33.7)	13 (28.9)
≥3 rd line	16 (17.4)	6 (13.3)

EVE, everolimus; LET, letrozole; LEUP, leuprorelin; ECOG, Eastern Cooperative Oncology Group; GnRH, gonadotropin-releasing hormone.

* Endocrine therapy is considered sensitive if outside of primary endocrine resistance.